Copyright ©The Author(s) 2023.
World J Gastroenterol. Jan 7, 2023; 29(1): 126-143
Published online Jan 7, 2023. doi: 10.3748/wjg.v29.i1.126
Table 1 Management of metabolic-associated fatty liver disease directed against the risk factors
Directed therapy
Supportive therapies
1Overweight and obesityAnti-obesity drugs, Bariatric surgery, lifestyle intervention (Calorie-restriction, dietary pattern, etc.)MAFLD: Newer agents targeting on cellular inflammation and oxidative stress.
2T2DMHypoglycemic agents like Metformin, GLP-1RAs, SGLT-2i, Thiazolidinediones and DPP-4 inhibitorsFibrotic MAFLD: Potential future anti-fibrotic agents.
3> 2 metabolic risksModulators of metabolism (Farnesoid X receptor agonsit, Peroxisome proliferator-activated receptor, fibroblast growth receptors, statins, aspirin)Cirrhosis Complications: Control portal hypertension and bacterial peritonitis prophylaxis. End-stage liver diseases: Liver transplantation.